Literature DB >> 11145039

Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus.

M Ramos-Casals1, J Font, M García-Carrasco, R Cervera, S Jiménez, O Trejo, G de la Red, J M Sánchez-Tapias, M Ingelmo.   

Abstract

OBJECTIVE: To determine the prevalence and clinical significance of hepatitis C virus (HCV) infection in patients with systemic lupus erythematosus (SLE).
METHODS: We investigated 134 consecutive SLE patients (121 women and 13 men; mean age 35 years) who fulfilled the 1982 revised criteria for SLE of the American College of Rheumatology. Two hundred consecutive volunteer blood donors were also studied. Serum from all patients and controls was tested for antibodies to HCV (by third generation enzyme-linked immunosorbent assay and confirmed by third generation recombinant immunoblot assay [RIBA-3]).
RESULTS: Antibodies to HCV were present in 18 patients with SLE (13%) and in 2 (1%) of the blood donors studied. Among the anti-HCV-positive group, HCV infection was confirmed (by RIBA-3 and polymerase chain reaction) in 15 SLE patients (11%) and in the 2 blood donors (1%) (P < 0.001). We observed a lower frequency of cutaneous SLE features (40% versus 76%; P = 0.01) and positivity for anti-double-stranded DNA (anti-dsDNA) (33% versus 81%; P < 0.001), and a higher frequency of hepatic involvement (93% versus 2%; P < 0.001), low C4 levels (73% versus 39%; P = 0.002), low CH50 levels (73% versus 44%; P = 0.03), and cryoglobulins (60% versus 22%; P = 0.02) in SLE patients with HCV infection compared with SLE patients without infection.
CONCLUSION: The prevalence of HCV infection in SLE patients was higher than in blood donors from the same geographic area. SLE HCV-positive patients showed a lower frequency of cutaneous SLE features and anti-dsDNA antibodies, and a higher prevalence of liver involvement, hypocomplementemia, and cryoglobulinemia. HCV testing should be considered in the diagnosis of SLE, especially in patients who lack the typical cutaneous features of SLE or who have low titers of autoantibodies, cryoglobulinemia, or liver involvement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145039     DOI: 10.1002/1529-0131(200012)43:12<2801::AID-ANR21>3.0.CO;2-V

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

1.  The diversity of autoantibodies to P-ribosomal: the infectious-autoimmunity plot.

Authors:  Yehuda Shoenfeld
Journal:  J Mol Med (Berl)       Date:  2007-09       Impact factor: 4.599

Review 2.  Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders.

Authors:  Deng-Ho Yang; Ling-Jun Ho; Jenn-Haung Lai
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

4.  Lupus-like glomerulonephritis: an autoimmune complication of hepatitis C infection.

Authors:  Liliane Hobeika; Monica Srivastava; Mai Vo; Marie D Philipneri; David S Brink; Nadia Wasi; Krista L Lentine
Journal:  CEN Case Rep       Date:  2012-03-27

Review 5.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

Review 6.  Infections and systemic lupus erythematosus.

Authors:  S Esposito; S Bosis; M Semino; D Rigante
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-09       Impact factor: 3.267

7.  Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection.

Authors:  K Kessenbrock; M J Fritzler; M Groves; P Eissfeller; C A von Mühlen; P Höpfl; M Mahler
Journal:  J Mol Med (Berl)       Date:  2007-08-01       Impact factor: 4.599

8.  Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases.

Authors:  S Aslanidis; T Vassiliadis; A Pyrpasopoulou; I Douloumpakas; C Zamboulis
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 3.650

9.  Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report.

Authors:  Iain J Abbott; Christina C Chang; Matthew J Skinner; Alison Street; Greg Perry; Catriona McLean; Edwina J Wright; Paul U Cameron
Journal:  J Med Case Rep       Date:  2009-06-10

Review 10.  Genetics and autoantibodies.

Authors:  Carlo Perricone; Nancy Agmon-Levin; Fulvia Ceccarelli; Guido Valesini; Juan-Manuel Anaya; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2013-07       Impact factor: 4.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.